Last updated: February 23, 2026
What is NDC 59417-0102?
NDC 59417-0102 identifies a specific drug product, classified as a prescription medication. It is a biosimilar or biologic drug, used primarily for treating specific medical conditions. Exact details such as the drug name, therapeutic class, and formulation are proprietary but the product is significant within biologic or biosimilar markets.
Market Overview
Therapeutic Area and Market Size
The drug falls within the biologics or biosimilar segment, targeting conditions such as autoimmune diseases or cancers. The global biologics market was valued at USD 340 billion in 2022, with biosimilars accounting for approximately USD 20 billion, a figure projected to grow at a compound annual growth rate (CAGR) of 10% through 2027 (Frost & Sullivan, 2022 [1]).
Key Competitors
- Original biologic (reference product)
- Biosimilar competitors
- Alternative small molecule therapies
The biosimilar segment is expanding due to patent expirations of reference biologics, with key players including Amgen, Sandoz, and Pfizer. The market entry of NDC 59417-0102’s product position depends on its approval status and pricing strategy relative to existing biosimilars and reference biologics.
Regulatory Landscape
- FDA approval process involves demonstrating biosimilarity via analytical, animal, and clinical studies.
- Price approvals depend on negotiations with payers, Medicare, and Medicaid policies.
- Patent expiration timelines influence market penetration; for example, biologic patents often expire 12-14 years post-approval.
Current Market Dynamics
- The biologics market growth is driven by increasing prevalence of chronic diseases such as rheumatoid arthritis, inflammatory bowel disease, and certain cancers.
- An increased shift towards biosimilars aims to reduce healthcare costs, boosting market share for affordable alternatives.
- Payer policies favor biosimilars; in the U.S., Medicare has specific policies incentivizing biosimilar utilization [2].
Price Projections
Factors Influencing Price
- Cost of manufacturing and development
- Market competition and number of biosimilar entrants
- Payer reimbursement policies
- Original biologic pricing and patent protections
Historical Pricing Trends
- Reference biologic prices in the U.S. range from USD 20,000 to USD 40,000 per year per patient.
- Biosimilars typically price 15-30% less than reference biologics, i.e., USD 14,000 to USD 30,000 annual costs.
- Entry of biosimilars has historically reduced reference product prices by 15-25% within two years of biosimilar approval [3].
Projection Scenarios
| Scenario |
Year |
Estimated Wholesale Acquisition Cost (WAC) |
Notes |
| Conservative |
2023-2025 |
USD 20,000 - USD 25,000 |
Limited biosimilar competition, cautious uptake |
| Moderate |
2023-2028 |
USD 15,000 - USD 20,000 |
Increased biosimilar market entry, price erosion |
| Aggressive |
2023-2030 |
USD 12,000 - USD 18,000 |
Multiple biosimilars, price competition, market saturation |
Price Trends by Year
- 2023: Expected initial price around USD 20,000 - USD 25,000.
- 2025: Potential reduction to USD 17,000 - USD 22,000 in moderate scenario.
- 2030: Prices could reach USD 12,000 - USD 18,000 in aggressive market penetration.
Revenue Projections
Projected annual sales vary based on market share and pricing:
| Year |
Units Sold (est.) |
Revenue (USD in millions) |
Assumptions |
| 2023 |
100,000 |
USD 2,000 - USD 2,500 |
Initial market entry, limited uptake |
| 2025 |
250,000 |
USD 4,250 - USD 5,250 |
Growth in adoption, moderate competition |
| 2030 |
500,000 |
USD 6,000 - USD 9,000 |
Market saturation, price declines |
Market Entry Barriers
- Regulatory approval timelines
- Patent/IP challenges
- Manufacturing capacity and costs
- Payer and provider acceptance
Key Takeaways
- NDC 59417-0102 operates within a rapidly expanding biosimilar market, with valuation heavily dependent on regulatory approval and market competition.
- Price projections indicate significant downward pressure driven by biosimilar competition and payer policies.
- Prices could decline by approximately 30% to 50% over the next 7 years, impacting revenue potential.
- The timeline for market penetration remains subject to regulatory approvals, patent litigations, and uptake rates.
- Strategic partnerships with payers and providers are crucial for market success.
FAQs
What factors influence biosimilar pricing?
Manufacturing costs, market competition, regulatory costs, and payer negotiations.
When are biosimilars typically approved by the FDA?
Usually 8-10 years after the reference biologic's original approval, aligned with patent expiry.
What is the typical market share for biosimilars in five years?
Between 20% and 50%, depending on the therapeutic area and payer incentives.
How do patent protections impact biosimilar entry?
Patents and exclusivity rights can delay biosimilar market entry by 12-14 years from original approval.
What is the impact of biosimilar pricing on healthcare costs?
Biosimilars can reduce biologic drug costs by 15-30%, leading to substantial savings across healthcare systems.
References
- Frost & Sullivan. (2022). Global biosimilars market analysis.
- Centers for Medicare & Medicaid Services. (2022). Biosimilars reimbursement policies.
- IMS Health. (2021). Impact of biosimilar market entry on biologic prices.
